Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum

Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective... To compare Pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA) with PCP in patients with non-RA connective tissue diseases (CTDs) in order to clarify the characteristics of the former. We extracted consecutive patients satisfying the following criteria for Bclinical PCP^: (1) positive plasma β-D-glucan, (2) PCP-compatible computed tomography findings of the lung, and (3) successful treatment with antipneumocystic antibiotics. Patients who underwent methylprednisolone Bpulse^ therapy or sufficient antibiotics to cure bacterial pneumonia were excluded. We used the t test, U test, or Fischer’s exact probability test to compare the two groups and Jonckheere-Terpstra’s test and Ryan’s procedure for the trend test. Thirty-five cases were extracted. The underlying rheumatic diseases were RA in 25 and non-RA CTDs in ten. At the onset of clinical PCP, the lymphocyte counts were 884 vs 357/mm (p < 0.001), PC-PCR positivity 64% vs 100% (p = 0.029), glucocorticoid dose 4.0 vs 17.5 mg PSL/day (p < 0.001), and methotrexate dose 8 vs 0 mg/week (p = 0.003). The PC-PCR-negative patients, observed only in the RA group, were all receiving methotrexate (MTX) therapy except one patient who was receiving high-dose pred- nisolone alone. All PC-PCR-positive patients were receiving glucocorticoid, TNF inhibitor, or a non-MTX http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Rheumatology Springer Journals

Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/differences-in-clinical-pneumocystis-pneumonia-in-rheumatoid-arthritis-AmX3eIoeQY
Publisher
Springer Journals
Copyright
Copyright © 2018 by International League of Associations for Rheumatology (ILAR)
Subject
Medicine & Public Health; Rheumatology
ISSN
0770-3198
eISSN
1434-9949
DOI
10.1007/s10067-018-4157-4
Publisher site
See Article on Publisher Site

Abstract

To compare Pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA) with PCP in patients with non-RA connective tissue diseases (CTDs) in order to clarify the characteristics of the former. We extracted consecutive patients satisfying the following criteria for Bclinical PCP^: (1) positive plasma β-D-glucan, (2) PCP-compatible computed tomography findings of the lung, and (3) successful treatment with antipneumocystic antibiotics. Patients who underwent methylprednisolone Bpulse^ therapy or sufficient antibiotics to cure bacterial pneumonia were excluded. We used the t test, U test, or Fischer’s exact probability test to compare the two groups and Jonckheere-Terpstra’s test and Ryan’s procedure for the trend test. Thirty-five cases were extracted. The underlying rheumatic diseases were RA in 25 and non-RA CTDs in ten. At the onset of clinical PCP, the lymphocyte counts were 884 vs 357/mm (p < 0.001), PC-PCR positivity 64% vs 100% (p = 0.029), glucocorticoid dose 4.0 vs 17.5 mg PSL/day (p < 0.001), and methotrexate dose 8 vs 0 mg/week (p = 0.003). The PC-PCR-negative patients, observed only in the RA group, were all receiving methotrexate (MTX) therapy except one patient who was receiving high-dose pred- nisolone alone. All PC-PCR-positive patients were receiving glucocorticoid, TNF inhibitor, or a non-MTX

Journal

Clinical Rheumatology – Springer Journals

Published: Jun 6, 2018

References

  • Pneumocystis jirovecii pneumonia
    Catherinot, E; Lanternier, F; Bougnoux, ME; Lecuit, M; Couderc, LJ; Lortholary, O
  • Serum indicators for the diagnosis of pneumocystis pneumonia
    Tasaka, S; Hasegawa, N; Kobayashi, S; Yamada, W; Nishimura, T; Takeuchi, T; Ishizaka, A
  • Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study
    Tokuda, H; Sakai, F; Yamada, H; Johkoh, T; Imamura, A; Dohi, M; Hirakata, M; Yamada, T; Kamatani, N; Kikuchi, Y; Sugii, S; Takeuchi, T; Tateda, K; Goto, H
  • Detection of Pneumocystis carinii with DNA amplification
    Wakefield, AE; Pixley, FJ; Banerji, S; Sinclair, K; Miller, RF; Moxon, ER; Hopkin, JM
  • Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study
    Kameda, H; Tokuda, H; Sakai, F; Johkoh, T; Mori, S; Yoshida, Y; Takayanagi, N; Taki, H; Hasegawa, Y; Hatta, K; Yamanaka, H; Dohi, M; Hashimoto, S; Yamada, H; Kawai, S; Takeuchi, T; Tateda, K; Goto, H
  • (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia
    Yasuoka, A; Tachikawa, N; Shimada, K; Kimura, S; Oka, S
  • Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients
    Salerno, D; Mushatt, D; Myers, L; Zhuang, Y; Rua, N; Calderon, EJ; Welsh, DA
  • β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study
    Boer, MG; Gelinck, LB; Zelst, BD; Sande, WW; Willems, LN; Dissel, JT; Jonge, R; Kroon, FP
  • Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS
    Limper, AH; Offord, KP; Smith, TF; Martin, WJ
  • Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis
    Ohosone, Y; Okano, Y; Kameda, H; Fujii, T; Hama, N; Hirakata, M; Mimori, T; Akizuki, M; Ikeda, Y
  • Katzenstein and Askin’s surgical pathology of non-neoplastic lung disease
    Katzenstein, AA
  • Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group
    Alarcón, GS; Kremer, JM; Macaluso, M; Weinblatt, ME; Cannon, GW; Palmer, WR; St Clair, EW; Sundy, JS; Alexander, RW; Smith, GJ; Axiotis, CA
  • Pneumocystis pneumonia associated with infliximab in Japan
    Harigai, M; Koike, R; Miyasaka, N
  • Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
    Lee, SH; Huh, KH; Joo, DJ; Kim, MS; Kim, SI; Lee, J; Park, MS; Kim, YS; Kim, SK; Chang, J; Kim, YS; Kim, SY
  • Pneumocystis pneumonia in a patient with type 2 diabetes mellitus
    Sanno, K; Hatanaka, N; Yamagishi, T; Kamemura, H; Hirano, Y; Kodaka, N; Miura, A; Kitahara, A; Sawata, T; Hosaka, K; Nakazawa, I